Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
2.8
USD
+1.82%
-6.35%
-32.45%
This article is reserved for members
Not a member ?
Free registration
HC Wainwright Adjusts Price Target on Leap Therapeutics to $5.50 From $7, Maintains Buy Rating
May. 14
MT
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 13
CI
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP
Apr. 09
CI
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
Mar. 19
MT
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration
Mar. 18
MT
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 18
CI
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 18
CI
Transcript : Leap Therapeutics, Inc. - Special Call
Jan. 23
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium
Jan. 16
CI
Transcript : Leap Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM
Jan. 10
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients
Jan. 02
CI
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating
Nov. 20
MT
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 13
CI
Top Premarket Decliners
23-10-16
MT
Top Premarket Decliners
23-10-09
MT
Baird Lowers Price Target on Leap Therapeutics to $20 From $30, Maintains Outperform Rating
23-08-15
MT
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating
23-07-13
MT
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients
23-07-12
CI
Raymond James Adjusts Price Target on Leap Therapeutics to $17 From $20, Keeps Outperform Rating
23-06-23
MT
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell Microcap Value Index
23-06-23
CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell 3000E Value Index
23-06-23
CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell 3000E Index
23-06-23
CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell Microcap Index
23-06-23
CI
Leap Therapeutics to Effect 10-for-1 Reverse Stock Split
23-06-20
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
More about the company
Average target price
11.38
USD
Spread / Average Target
+306.25%
Consensus
1st Jan change
Capi.
-32.45% 107M +7.52% 113B +11.38% 106B +0.61% 22.27B -12.64% 22.22B -4.27% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**